SPA
LGND icon

Sherbrooke Park Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Sherbrooke Park Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,433
Closed -$475K – 786
2024
Q4 		$475K Sell
4,433
-1,260
-22% -$142K 0.15% 233
2024
Q3 		$570K Buy
+5,693
New +$573K 0.13% 255

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's LGND Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 4,433 shares — an estimated $475K sold.

Sherbrooke Park Advisers first reported a position in LGND in Q3 2024 and held it in 2 quarters. The position peaked at $570K in Q3 2024. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 4,433 Ligand Pharmaceuticals shares in Q1 2025, an estimated $475K.
  • Sherbrooke Park Advisers first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Ligand Pharmaceuticals position peaked at $570K in Q3 2024.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.